FASEB's The Reversible Protein Acetylation in Health and Disease Conference

FASEB 健康与疾病中的可逆蛋白质乙酰化会议

基本信息

批准号：
10230422
负责人：
Jessica K Tyler
金额：
$ 0.8万
依托单位：
FEDERATION OF AMER SOC FOR EXPER BIOLOGY
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-09-01 至 2023-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10230422
关键词：
Acetylation Acetyltransferase Aging Ally American Antineoplastic Agents Architecture Area Basic Science Binding Binding Proteins Biochemistry Biological Biology Bromodomain Cancer Etiology Carbon Cations Cell Cycle Progression Cell Proliferation Cells Cellular biology Charge Chemicals Chemoprevention Clinical Clinical Research Collaborations Communities Country DNA Repair DNA biosynthesis Deacetylase Development Dietary Intervention Disease Docking Drug Targeting Eating Enzyme Interaction Enzymes Etiology European FDA approved Faculty Female Fertilization Fostering Gene Expression Genetic Genetic Transcription Genome Genome Stability Germany Goals Growth Growth and Development function Health Histone Deacetylase Histone Deacetylase Inhibitor Homeostasis Human Immune response Industrialization Industry International Investigation Italy Knowledge Link London Longevity Lysine Malignant Neoplasms Medical Mentors Metabolic Diseases Metabolism Methylation Mitochondria Modification Molecular Molecular Biology Molecular Mechanisms of Action Montana N-terminal New Agents Nuclear Oral Participant Pathway interactions Patients Pattern Pharmacology Phosphorylation Play Portugal Post-Translational Protein Processing Premature aging syndrome Prize Process Protein Acetylation Protein Secretion Proteins Public Health Puerto Rico Reader Regulation Reporting Research Research Personnel Resort Role Scientist Side Signal Transduction Sirtuins Site Structure Sumoylation Pathway Surface Talents Technology Testing Therapeutic Therapeutic Intervention Therapeutic Uses Time Training Tumor Suppressor Genes Underrepresented Minority age related base cancer cell cancer therapy career career development drug discovery epigenetic regulation epigenetic silencing epigenome graduate student histone acetyltransferase human disease improved inhibitor/antagonist innovation insight interest meetings novel therapeutic intervention novel therapeutics overexpression palmitoylation posters prevent protein function response stem cell function stem cells success summer research symposium therapeutic target

项目摘要

Abstract Over the past few years, the “epigenetic” regulation of the genome has become increasingly important to understanding both the etiology and fundamental mechanisms of aging and age-related diseases. Key to epigenetic regulation are two classes of lysine-modifying enzymes, the histone deacetylases (sirtuins and HDACs) and the histone acetyltransferases (HATs), also known as erasers and writers, respectively. Acetyl- lysine neutralizes the cationic charge relative to the naked Lys sidechain and also creates an attractive surface for binding to proteins containing bromodomains, also known as reader proteins. These acetyl-Lys writers, erasers, and readers are critical for maintaining normal expression patterns, cell cycle progression, DNA repair, stem cells, mitochondria, cell fate, and differentiation. Alterations in the functions of these acetyl-Lys related proteins have been linked to epigenetic silencing of gene expression including tumor suppressor genes, leading to cancer cell proliferation. Moreover, changes in acetyl-Lys pathways are believed to contribute to a variety of other diseases and aging mechanisms. Several broad spectrum HDAC inhibitors have been approved by FDA to treat various cancers. Their precise molecular mechanisms in controlling cancer and influencing other biomedical processes remain elusive. Targeting HATs and HDACs for therapeutic purposes has been an area of great interest and success, and exciting new progress has also been made in recent years in targeting interactions between readers and acetylated lysines in cancer and other diseases. As the only conference dedicated to protein acetylation, this biannual meeting plays an essential role in bringing together more than 40 world leaders and ~120 participants. A primary objective is to transfer knowledge and foster collaboration between basic academic researchers, clinical scientists, and industrial researchers to understand how lysine acetylation controls human health and how to prevent and treat a diverse set of cancers and age-related diseases. A second objective is to foster the development and interests of younger investigators to help support their career development. The participants stay and eat at the meeting venue so they have ample time to for informal brainstorming and networking. There are 16 planned talks from junior scientists selected from the submitted abstracts and poster prize winners, which is important for their career development. We will also have a panel discussion on professional development and career options, aimed to provide further support for the young investigators. Moreover, there will be a diversity networking session, and multiple meet the speaker sessions that will be highlighted at the meeting. This meeting is particularly timely because of a linkage of acetylation, metabolism, and cancer. Furthermore, exciting new fundamental discoveries are continuing to be reported, such as the discovery of new lysine post-translational modifications (e.g. 3-hydroxybutyryl lysine and palmitoyl lysine) that can be removed by sirtuins or HDACs, and the discovery that these modifications can regulate transcription, cell signaling, and protein secretion. Therefore, support is requested for the 8th biannual FASEB conference on reversible protein acetylation in health and disease to be held in Dorado, Puerto Rico on August 9-14, 2021.

抽象的在过去的几年里，基因组的“表观遗传”调控变得越来越重要。了解衰老和年龄相关疾病的病因和基本机制。表观遗传调控是两类赖氨酸修饰酶，即组蛋白脱乙酰酶（sirtuins 和 HDAC）和组蛋白乙酰转移酶（HAT），也分别称为擦除器和写入器。赖氨酸中和了相对于裸露的赖氨酸侧链的阳离子电荷，并且还形成了有吸引力的表面用于与含有溴结构域的蛋白质（也称为读取蛋白）结合，橡皮擦和读取器对于维持正常表达模式、细胞周期进程、DNA 至关重要修复、干细胞、线粒体、细胞命运和这些乙酰赖氨酸功能的改变。相关蛋白质与基因表达的表观遗传沉默有关，包括肿瘤抑制因子此外，乙酰-赖氨酸途径的变化被认为会导致癌细胞增殖。几种广谱 HDAC 抑制剂已被 FDA 批准用于治疗各种癌症，其控制的精确分子机制。针对 HAT 和 HDAC 进行治疗的研究仍然难以捉摸。用途一直是人们极大兴趣和成功的领域，并且在以下方面也取得了令人兴奋的新进展近年来针对癌症和其他疾病中阅读器和乙酰化赖氨酸之间的相互作用。作为唯一致力于蛋白质乙酰化的会议，这个一年两次的会议在促进 40 多位世界领导人和约 120 名参与者齐聚一堂，主要目标是传播知识和成果。促进基础学术研究人员、临床科学家和工业研究人员之间的合作了解赖氨酸乙酰化如何控制人类健康以及如何预防和治疗多种癌症第二个目标是促进年轻人的发展和兴趣。调查员帮助支持他们的职业发展，以便参与者在会议地点住宿和吃饭。他们有充足的时间进行非正式的头脑风暴和交流。初级人员计划进行 16 场演讲。从提交的摘要和海报奖获得者中选出的科学家，这对他们的职业生涯很重要我们还将就职业发展和职业选择进行小组讨论，旨在此外，还将举办多元化网络会议，并为年轻研究人员提供进一步的支持。多次见面的演讲者会议将在会议上强调，这次会议特别及时。此外，由于乙酰化、代谢和癌症之间的联系，令人兴奋的新基础。不断有新的发现被报道，例如新的赖氨酸翻译后修饰的发现（例如 3-羟基丁酰赖氨酸和棕榈酰赖氨酸）可被 Sirtuins 或 HDAC 去除，并且发现这些修饰可以调节转录、细胞信号传导和蛋白质分泌。请求支持第八届 FASEB 会议，该会议每年两次，主题是健康和可逆蛋白质乙酰化该疾病将于 2021 年 8 月 9 日至 14 日在波多黎各多拉多举行。